SHOULD AROMATASE INHIBITORS BE USED AS MAINTENANCE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS?

被引：0
|
作者：
Heinzelmann-Schwarz, V. [1 ]
Knipprath-Meszaros, A. M. [1 ]
Francis, J. [2 ]
Stadlmann, S. [3 ]
Vigo, F. [1 ]
Schoetzau, A. [2 ]
Singer, G. [3 ]
Vetter, M. [1 ]
机构：
[1] Univ Hosp Basel, Gynecol Canc Ctr, Basel, Switzerland
[2] Ovarian Canc Res Ctr, Dept Biomed, Basel, Switzerland
[3] Cantonal Hosp Baden, Inst Pathol, Baden, Switzerland
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2017年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO7-0583
引用
收藏
页码：307 / 307
页数：1
相关论文
共 50 条
  • [1] SHOULD AROMATASE INHIBITORS BE USED AS MAINTENANCE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS?
    Heinzelmann-Schwarz, V.
    Knipprath-Meszaros, A. M.
    Francis, J.
    Stadlmann, S.
    Vigo, F.
    Schoetzau, A.
    Singer, G.
    Vetter, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1547 - 1547
  • [2] Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients
    Heinzelmann-Schwarz, V.
    Meszaros, A. Knipprath
    Stadlmann, S.
    Jacob, F.
    Schoetzau, A.
    Russell, K.
    Friedlander, M.
    Singer, G.
    Vetter, M.
    GYNECOLOGIC ONCOLOGY, 2018, 148 (01) : 79 - 85
  • [3] Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma.
    Vandenberg, Cassandra J.
    Ho, Gwo-Yaw
    Nesic, Ksenija
    Swisher, Elizabeth M.
    Grimmond, Sean M.
    Wakefield, Matthew J.
    Barker, Holly E.
    Bowtell, David D.
    Scott, Clare L.
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer
    Trudel, Dominique
    Avarvarei, Luminita-Mihaela
    Orain, Michele
    Turcotte, Stephane
    Plante, Marie
    Gregoire, Jean
    Kappelhoff, Reinhild
    Labbe, David P.
    Bachvarov, Dimcho
    Tetu, Bernard
    Overall, Christopher M.
    Bairati, Isabelle
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (06)
  • [5] Advances in small molecule maintenance therapies for high-grade serous ovarian cancer
    Fischetti, Margherita
    Di Donato, Violante
    Palaia, Innocenza
    Perniola, Giorgia
    Tomao, Federica
    Perrone, Chiara
    Giancotti, Antonella
    Di Mascio, Daniele
    Monti, Marco
    Muzii, Ludovico
    Benedetti Panici, Pierluigi
    Bogani, Giorgio
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (01) : 65 - 72
  • [6] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Robert D. Morgan
    Andrew R. Clamp
    D. Gareth R. Evans
    Richard J. Edmondson
    Gordon C. Jayson
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 647 - 658
  • [7] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Morgan, Robert D.
    Clamp, Andrew R.
    Evans, D. Gareth R.
    Edmondson, Richard J.
    Jayson, Gordon C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
  • [8] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
  • [9] Personalising Treatment for High-Grade Serous Ovarian Carcinoma
    Cojocaru, E.
    Parkinson, C. A.
    Brenton, J. D.
    CLINICAL ONCOLOGY, 2018, 30 (08) : 515 - 524
  • [10] High-grade serous ovarian cancer: the clone wars
    Aleksander Salomon-Perzyński
    Magdalena Salomon-Perzyńska
    Bogdan Michalski
    Violetta Skrzypulec-Plinta
    Archives of Gynecology and Obstetrics, 2017, 295 : 569 - 576
12345